Numerous studies have been carried out in the mouse model, investigating the role of the cannabinoid receptor type 1 (CB1). However, mouse CB1 (mCB1) receptor differs from human CB1 (hCB1) receptor in 13 amino acid residues. Two splice variants, hCB1a and hCB1b, diverging in their amino-termini, have been reported to be unique for hCB1 and, via different signaling properties, contribute to CB1 receptor physiology and pathophysiology. We hypothesized that splice variants also exist for the mCB1 receptor and have different signaling properties. On murine hippocampal cDNA, we identified two novel mCB1 receptor splice variants generated by splicing of introns with 117 bp and 186 bp in the N-terminal domain, corresponding to deletions of 39 or 62 amino acids, respectively. The mRNAs for the splice variants mCB1a and mCB1b are expressed at low levels in different brain regions. Western blot analysis of protein extracts from stably transfected HEK293 cells indicates a strongly reduced glycosylation because of the absence of two glycosylation sites in mCB1b. On-cell western analysis in these stable lines revealed increased internalization of mCB1a and mCB1b upon stimulation with the agonist WIN55,212-2 as compared to mCB1. Results also point toward an increased affinity to SR141716 for mCB1a, as well as slightly enhanced inhibition of neurotransmission compared to mCB1. In mCB1b, agonist-induced MAPK phosphorylation was decreased compared to mCB1 and mCB1a. Identification of mouse CB1 receptor splice variants may help to explain differences found between human and mouse endocannabinoid systems and improve the understanding of CB1 receptor signaling and trafficking in different species.
system can cause many pathologies (Maccarrone et al. 2014; Di Marzo et al. 2015; Lutz et al. 2015) . Many pre-clinical studies investigating the role of CB1 receptor signaling have been carried out in mice because of the versatility and availability of many transgenic models (Lutz 2014) . CB1 receptor function can be very well studied in mouse, as the receptor is well conserved between mouse and human with 97% amino acid identity and 90% nucleotide identity (Abood 2005) . However, for the human CB1 (hCB1) receptor, two splice isoforms differing at the N-terminus of the receptor have been identified (Shire et al. 1995; Ryberg et al. 2005; Xiao et al. 2008) and were described to contribute to normal physiological processes (Bagher et al. 2013) . Furthermore, possible implications in pathophysiology have recently been proposed (Gonz alez-Mariscal et al. 2016) .
The first variant, hCB1a, has an altered N-terminal amino acid sequence truncated by 61 amino acid residues with a substitution of the first 89 amino acids for a different 28-residue sequence because of a frame shift and the use of a different start codon (Shire et al. 1995) . The second variant, hCB1b has an in-frame deletion of 33 amino acids also in the hCB1 receptor amino terminus (Ryberg et al. 2005) . Both hCB1a and hCB1b mRNAs are found in several tissues including brain (Shire et al. 1995; Ryberg et al. 2005; Xiao et al. 2008 ) and hCB1a and hCB1b receptor proteins are coexpressed with hCB1 throughout the brain (Bagher et al. 2013) . Although the membrane location and trafficking of hCB1a and hCB1b does not differ from hCB1 (Straiker et al. 2012) , signaling properties of the human receptor splice variants are distinct from one another as well as from rodent CB1 receptors (Ryberg et al. 2005; Xiao et al. 2008; Straiker et al. 2012) . Co-expression of hCB1 and each of the splice variants was shown to increase cell surface expression of the human cannabinoid hCB1 receptor and agonist-induced ERK phosphorylation (Bagher et al. 2013) . The two human splice variants rescued depolarization-induced suppression of excitation in a similar range as the rat CB1 receptor when expressed in cultured hippocampal neurons from CB1 receptor-deficient mice, whereas the hCB1 receptor signaled less robustly under identical conditions (Straiker et al. 2012) .
The classical splice donor and acceptor sequences that are present in the coding sequence of the human CB1 receptor gene are not conserved in the mouse CB1 receptor gene. Thus, it was assumed that the N-terminal splicing is unique for the human CB1 receptor (Howlett et al. 2002; Xiao et al. 2008) . However, in this study, we identified two splice variants for the mouse CB1 receptor (mCB1) and characterized their trafficking and signaling properties.
Materials and methods

Animals
All experimental protocols conducted in Germany were carried out in accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC) and approved by the Ethical Committee on animal care and use of Rhineland-Palatinate (23 177-07/A 10-1-009), Germany. Experiments conducted in the United States were approved by the Institutional Animal Care and Use Committee of Indiana University Bloomington and conform to the Guidelines of the National Institutes of Health on the Care and Use of Animals. Mice (C57BL/6N (RRID:IMSR_CRL:27) for the identification of novel transcripts and CB1 knockout in CD1 (Ledent et al. 1999; RRID:MGI:4881723) background for neuronal cultures) derived from in-house breeding colonies and were housed in a temperature-and humidity-controlled room (22°C AE 1; 50 AE 1%) with a 12-12 h light-dark cycle (lights on at 7 am) and had access to food and water ad libitum.
Identification of novel transcripts
Animals (5 males, C57BL/6N, 8-12 weeks) were killed by decapitation under deep isoflurane anesthesia. Brains were isolated and snap-frozen on dry-ice. Mounted on Tissue Tek (Polysciences, Warrington, PA, USA), coronal sections were cut on a cryostat Microtome HM560 (Microm, Walldorf, Germany). Brains were trimmed until the area of interest was reached (distance from bregma according to Paxinos and Franklin 2008) . Tissue punches were taken with sample corers (Fine Science Tools, Heidelberg, Germany) from infralimbic cortex (AP +1.94, ML AE0.00, DV +3.10; 1 mm diameter, 0.5 mm depth), caudate putamen (AP +1.10, ML AE1.80, DV +3.10; 1 mm diameter, 1 mm depth), basolateral amygdala (AP À0.82, ML AE2.80, DV +4.70; 0.8 mm diameter, 1.2 mm depth), dorsal hippocampus (AP À1.52, ML AE1.40, DV +1.75; 1 mm diameter, 1 mm depth), and cerebellum (AP +5.80, ML AE1.20, DV +2.10; 2 mm diameter, 2 mm depth) and were stored at À80°C.
Frozen tissue samples were homogenized in RLT buffer (RNeasy Mini-Kit; Qiagen, Hilden, Germany) with a Precellys 24 (Peqlab, Erlangen, Germany) at 6000 rpm for 20 s. Total RNA was isolated using the RNeasy Mini-Kit (Qiagen). Total RNA was reverse-transcribed using the High Capacity cDNA Reverse Transcription Kit with random primer hexamers (Applied Biosystems, Carlsbad, CA, USA).
Primer pairs flanking putative introns were designed using Vector NTI software (Invitrogen, Darmstadt, Germany; forward primer: 5'-GGTTATGAAGTCGATCTTAGACGG; reverse primer: 5'-TCCCCACACTGGATGTTGT). PCR on cDNA templates was performed with Phusion High-Fidelity DNA Polymerase (New England Biolabs (NEB), Frankfurt, Germany). Conditions were 95°C 5 min, followed by 30 cycles of 95°C 30 s, 56°C 30 s, 72°C 90 s, followed by a final extension of 72°C 5 min.
PCR-amplified DNA was separated on 1.5% (w/v) agarose gels and DNA bands were extracted using the NucleoSpin Extract II Kit (Macherey Nagel, Dueren, Germany). A-overhangs were added using a Taq-Polymerase (Promega, Madison, WI, USA). PCR products were cloned into a TOPO-TA vector according to the manufacturer's instructions (Eurofins MWG Operon, Ebersberg, Germany). The intron and exon sequences were identified by comparing the sequences of cDNA clones with the genomic sequence of the mouse CB1 receptor gene using Nucleotide BLAST (http://blast.ncbi.nlm.nih.gov/).
Quantitative PCR using TaqMan assays Quantification of cDNA was performed with an ABI 7300 real-time PCR cycler (Applied Biosystems). The cDNA was amplified using commercial FAM dye-labeled TaqMan assays (Applied Biosystems) for mouse CB1 cannabinoid receptor (Cnr1; Mm00432621_s1) and mouse glucuronidase beta (Gusb; Mm00446953_m1). For mCB1a and mCB1b, custom Taqman assays were designed using Primer Express Software (Applied Biosystems): mCB1a forward primer 5'-GATACCACCTTCCGTACCATCAC, mCB1a reverse primer 5'-AATGTTGGTTGTGTCTCCTTTGATAT, mCB1a FAM-labeled reporter 5'-TCCTCTACGTGGGCTC; mCB1b forward primer 5'-GATACCACCTTCCGTACCATCAC, mCB1b reverse primer 5'-GTTGTCCTCGTTCTCCTGAATGT, mCB1b FAM-labeled reporter 5'-ACAGACCTCCTCTACGTGG. Primer pairs were pre-tested for specificity in a non-quantitative PCR. PCR was performed in a volume of 20 lL containing 10 lL TaqMan Gene Expression Mastermix (Applied Biosystems), 1 lL TaqMan assay and 9 lL cDNA (pre-diluted to approximately 3 ng/lL) with the cycle protocol 50°C 2 min, 95°C 10 min, 50 cycles of 95°C for 15 s and 60°C for 1 min. The expression levels of the quantified transcripts were normalized to that of the reference gene Gusb. To compare the expression levels of the novel splice variants mCB1a and mCB1b with that of mCB1, the expression levels of mCB1a and mCB1b were normalized to the expression level of mCB1 (assay Cnr1).
Cloning of mCB1a and mCB1b
Hippocampal cDNA was used to clone mCB1a and mCB1b in a two-step process (see Figure S1 for details, and Table S1 and S2 for primer sequences and PCR conditions, respectively). PCRs were performed with Phusion High Fidelity DNA Polymerase (NEB). PCR products from interim and final cloning steps were purified by excision of bands from 1% agarose gel. DNA was purified using the NucleoSpin Extract II Kit (Macherey Nagel). PCR products were then digested with the restriction enzymes KpnI and NotI (NEB) and purified by gel extraction as above. The vector pcDNA3 was also digested with KpnI and NotI, dephosphorylated with Antarctic phosphatase (NEB). Vector backbone and insert were then ligated with T4 DNA ligase (NEB). Ligated DNA was transfected into chemically competent DH5a E. coli, positive clones were picked and expanded (Sambrook et al. 2001) . Plasmid DNA was purified with the NucleoSpin Plasmid Kit (Macherey Nagel). To verify correct cloning, the plasmids were sequenced.
A hemagglutinin (HA)-epitope tag was added to each splice variant via PCR, and these labeled constructs were then used to generate stable cell lines. Primers were designed using ApE cDNA plasmid software (http://biologylabs.utah.edu/jorgensen/wayned/ ape/). The 5' primer (5'-GCGGATCCACCATGGCATACCCA-TATGATGTCCCCGACTACGCGAAGTCGATCTTA-GACGGCCTTG) consisted of a BamHI restriction site followed by a strong Kozak consensus sequence in frame with the HA11 epitope, and the common beginning of the three variants. The antisense primer (5'-GGCGCGGCCGCTCACAGAGCCTCGGCAGA) contained a NotI restriction site directly after the stop codon. The PCR products for the three mCB1 variants were then digested with BamHI and NotI and subcloned into both CAG and pcDNA3 vectors. The constructs were verified by sequencing.
Cell culture and transfection HEK293 cells were grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (FBS) and 100 units/mL penicillin and 100 lg/mL streptomycin (all substances from Gibco, Carlsbad, CA, USA) at 37°C in a 5% CO 2 humidified incubator and split the day before transfection. Cells were transfected with the CB1 receptor variant-containing plasmids via Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Stable cell lines of all constructs were generated by selection using Geneticin (G418; Invitrogen). G418-resistant colonies were evaluated for the CB1 surface expression by live cell immunostaining using an antibody directed toward the N-terminal extracellular HA11 epitope tag (Cat# MMS-101P; Covance, Berkeley, CA, USA: RRID:AB_291230) and a fluorescein isothiocyanate secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA, USA; RRID:AB_2340792). Clones expressing uniform and moderate to high levels of CB1 receptor were expanded and used for subsequent experiments. The relative levels of the expression of CB1 receptor between the novel-variant and wild-type lines were not significantly different (see Fig. 3a for western blots including GAPDH internal standard). Three stable cell lines were generated and analyzed for each CB1 receptor variant.
For neuronal cell culture for autaptic neurons, mouse hippocampal neurons isolated from the cornu ammonis 1 to cornu ammonis 3 region were cultured on microislands as previously described (Furshpan et al. 1976; Bekkers and Stevens 1991) . Neurons were obtained from CB1 knockout animals of either sex (at postnatal day 0-2, killed via rapid decapitation without anesthesia) and plated onto a feeder layer of hippocampal astrocytes that had been laid down previously (Levison and McCarthy 1991) . Cultures were grown in high-glucose (20 mM) minimum essential media containing 10% horse serum, without mitotic inhibitors and used for recordings after 8 days in culture and for no more than 3 h after removal from culture medium (Straiker and Mackie 2005) . All electrophysiological experiments were performed exclusively on excitatory neurons.
We transfected neurons using a calcium phosphate-based method adapted from Jiang et al. (2004) . Briefly, plasmids for the protein of interest and for an EYFP expression plasmid (2 lg/well) were combined with 2 M CaCl 2 and water and then gradually added to HEPES-buffered saline (HBS, 130 mM NaCl, 5.4 mM KCl, 1.8 mM MgCl 2 , and 10 mM HEPES, pH 7.5); the resulting mixture was added to the serum-free neuronal media. Coverslips were incubated with this mixture for 2.5 h, whereas extra media were placed in a 10% CO 2 incubator to induce acidification. At the end of 2.5 h, the reaction mixture was replaced with acidified serum-free media for 20 min. After this, cells were returned to their home wells. Each dataset was taken from at least two different neuronal platings.
Western blot
Stably transfected HEK293 cell lines grown to approximately 90% confluency in 6-well dishes were chilled on ice for 5 min. Following a wash with ice-cold 19 phosphate-buffered saline (PBS) (137 nM NaCl, 10 mM NaH 2 PO 4 , 2.7 mM KCl, pH 7.4), cells were covered with 200 lL lysis buffer (100 mM Tris (pH 7.4), 150 mM NaCl, 0.5% CHAPS, 1 mM EDTA, 6 mM MgCl 2 , and 100 mM phenylmethylsulfonyl fluoride) and incubated on ice for 5 min. Cells were then scraped and lysates were sonicated and spun down at 10 000 g and 4°C. The supernatant was collected and protein concentration was determined by the method of Bradford (Bradford 1976) . The samples were normalized to total protein, and 25 lg protein of each sample was run on a 10% Tris-glycine sodium dodecyl sulfatepolyacrylamide gel electrophoresis. The separated proteins were transferred to nitrocellulose and immunoblotting was performed using a mouse monoclonal anti-HA11 antibody and anti-GAPDH antibody (Cat# 649201; Biolegend, San Diego, CA, USA: RRID: AB_2107422). Both primary antibodies were diluted 1 : 1000 in Odyssey blocking buffer (LI-COR Biosciences, Lincoln, NE, USA). A secondary antibody, goat anti-mouse conjugated IR680 dye (Cat# A21057; Invitrogen; RRID:AB_141436) was diluted 1 : 5000 in a 1 : 1 mixture of PBS and Odyssey blocking buffer. Western blots were scanned on an Odyssey near-IR scanner (LI-COR Biosciences), and images were processed using Photoshop CE.
Quantitative internalization assay
Agonist-induced internalization of the mCB1 receptor and its splice variants was assessed in stably transfected HEK293 cell lines as described previously (Daigle et al. 2008b) . Briefly, HEK293 cells stably expressing mCB1, mCB1a, or mCB1b were seeded onto poly-D-lysine coated 96-well plates and grown until~95% confluent. Before drug treatment, cells were washed once in HBS containing 0.2 mg/mL bovine serum albumin (Sigma-Aldrich, St. Louis, MO, USA) and patted dry. Cells were then incubated in HBS/ bovine serum albumin containing R-( (SR141716) with concentrations and incubation times indicated in the results. For internalization in the presence of antagonist, 10 nM SR141716 was applied together with WIN55,212-2 and incubated for 30 min. At the end of the incubation, wells were emptied and the plate was placed on ice. Cells were immediately fixed in 4% paraformaldehyde (PFA) for 20 min at 22°C. Cells were washed five times for 5 min in PBS and blocked for 60 min with LI-COR Odyssey Blocking Buffer (LI-COR Biosciences). Cells were then incubated overnight at 4°C in mouse monoclonal anti-HA11 antibody (1 : 150, Cat# 901503; BioLegend; RRID:AB_2565005) with gentle shaking. The following day, cells were washed five times for 5 min in Tris-buffered saline (TBS) containing 0.05% Tween-20 (TBST; Tris-Base 10 mM, 137 mM NaCl, 0.05% Tween-20, pH 7.4) and then incubated for 1 h in the dark with donkey anti-mouse IgG conjugated to IRDye 800CW (1 : 800; Rockland Immunochemicals, Gilbertsville, PA, USA; RRID:AB_1660938) in Odyssey Blocking Buffer. Cells were then washed four times for 5 min in TBST in darkness. After a short rinse in TBS, the immunocomplex was visualized on a LI-COR Odyssey near-IR scanner (LI-COR Biosciences).
Immunocytochemistry
Cells were plated onto coverslips coated with Poly-D-lysine and grown overnight. They were then washed in cold PBS followed by cold 4% PFA for 20 min at 22°C. Following five washes in PBS, cells were covered with wheat germ agglutinin (WGA488, Cat# W11261; Invitrogen) diluted 1 : 300 in PBS for 5 min at 22°C. Samples were washed three times with PBS and immediately blocked in blocking buffer for 45 min at 22°C. Mouse anti HA-11 antibody was added (1 : 150). Cells were incubated overnight at 4°C. The next day, cells were washed six times with TBST and incubated in secondary antibody (donkey anti-mouse Alexa594, Cat# 715-585-150, RRID:AB_2340854; Jackson Immunoresearch) diluted 1 : 500. Coverslips were then incubated for 60 min at 22°C, washed five times in PBS and three times in water. After allowing to dry, coverslips were mounted using Fluoromount-G with 4 0 ,6-diamidino-2-phenylindole (DAPI) (Cat# 00-4959-52; Invitrogen). Images were collected on a Leica SP-5 (LMIC, Indiana University) using UV, 488 and 594 nm lasers. Images were processed using NIH ImageJ (NIH, Bethesda, MD, USA) and Photoshop CS5 (Adobe Systems, San Jose, CA, USA; version 12.0).
Quantitative measurement of MAPK phosphorylation
Stably expressing HEK293 cells were seeded on poly-D-lysine coated 96-well plates and grown until~95% confluent. Cells were serum-starved overnight in 100 lL Dulbecco 0 s modified Eagle 0 s medium containing penicillin/streptomycin and only 0.1% FBS prior to the experiment. Before drug treatment, medium containing 0.1% FBS was replaced and an additional 100 lL medium with WIN55,212-2 was added to a final concentration of 100 nM. Cells were then incubated at 37°C for 5-120 min. After drug treatment, medium was removed and the cells were fixed by immediate addition of 100 lL ice-cold 4% PFA and incubated for 15 min on ice and for an additional 30 min at 22°C. Cell membranes were permeabilized by addition of 100 lL ice-cold methanol and incubation at À20°C for 20 min. Cells were then washed five times for 5 min with Triton wash solution (0.1% Triton X-100 in PBS or TBS) and patted dry. Cells were blocked for 1.5 h in 100 lL Odyssey Blocking Solution with gentle shaking and incubated overnight at 4°C with anti-phospho-p44/42 MAPK antibody (Thr202/Tyr204; 20G11; Cell Signaling Technologies, Danvers, MA, USA: RRID:AB_331772) diluted 1 : 200 in Odyssey Blocking buffer. Cells were then washed five times for 5 min in TBST, briefly rinsed in PBS and incubated for 1.5 h with donkey antimouse IgG conjugated to IRDye 800CW (1 : 800) in Odyssey Blocking Buffer protected from light. Cells were washed five times for 5 min in TBST and patted dry. Immunofluorescence was scanned with a LI-COR Odyssey near-IR scanner (LI-COR Biosciences). Integrated intensity values were used for analysis and were averaged and normalized to basal level activity.
Electrophysiology
When a single neuron is grown on a small island of permissive substrate, it forms synapses -or 'autapses' -onto itself. All electrophysiology experiments were performed on isolated autaptic neurons. Whole-cell, voltage-clamp recordings from autaptic neurons were carried out at 22°C using an Axopatch 200B amplifier (Axon Instruments, Burlingame, CA, USA). The extracellular solution contained (mM) NaCl 119, KCl 5, CaCl 2 2, MgCl 2 1, glucose 30, and HEPES 20. Recording pipettes of 1.8-3 MO were filled with solution containing (mM): potassium gluconate 121.5, KCl 17.5, NaCl 9, MgCl 2 1, HEPES 10, EGTA 0.2, MgATP 2, and LiGTP 0.5. Access resistance was monitored and only cells with a stable access resistance were included for data analysis. Conventional stimulus protocol: the membrane potential was held at -70 mV and excitatory post-synaptic currents (EPSCs) were evoked every 20 s by triggering an unclamped action current with a 1.0 ms depolarizing step. The resultant evoked waveform consisted of a brief stimulus artifact and a large downward spike representing inward sodium currents, followed by the slower EPSC. The size of the recorded EPSCs was calculated by integrating the evoked current to yield a charge value (in pC). Calculating the charge value in this manner yields an indirect measure of the amount of neurotransmitter released, whereas minimizing the effects of cable distortion on currents generated far from the site of the recording electrode (the soma). Data were acquired at a sampling rate of 5 kHz.
Depolarization-induced suppression of excitation (DSE) stimuli: After establishing a 10-20 s 0.5 Hz baseline, DSE was evoked by depolarizing to 0 mV for 50 ms, 100 ms, 300 ms, 500 ms, 1 s, 3 s, and 10 s, followed in each case by resumption of a 0.5 Hz stimulus protocol for 20-80+ s, allowing EPSCs to recover to baseline values. This approach allowed us to determine the sensitivity of the synapses to DSE induction. To allow comparison, baseline values (prior to the DSE stimulus) are normalized to one. DSE inhibition values are presented as fractions of 1, i.e., a 50% inhibition from the baseline response is 0.50 AE standard error of the mean. The x-axis of DSE depolarization-response curves are log-scale seconds of the duration of the depolarization used to elicit DSE.
Depolarization-response curves are obtained to determine pharmacological properties of endogenous 2-AG signaling by depolarizing neurons for progressively longer durations (50 ms, 100 ms, 300 ms, 500 ms, 1 s, 3 s, and 10 s). The data are fitted with a nonlinear regression, allowing calculation of an ED 50 , the effective dose or duration of depolarization at which a 50% inhibition is achieved. Statistical significance in these curves is based on non-overlapping 95% confidence intervals of the ED 50 's.
Data analysis
The results were analyzed using Prism6 Software (GraphPad, La Jolla, CA, USA) or SPSS Statistics Software version 19 (IBM, Armonk, NY, USA). Differences were considered statistically significant at p < 0.05. All data are expressed as mean AE SEM. Statistical analysis of the expression of the splice variants with shortened N-terminal were performed with one-way ANOVA. Assays for quantitative measurement of internalization and p44/p42 MAPK phosphorylation were analyzed using two-way ANOVA. Significant genotype effects were further analyzed using Bonferroni's post hoc analysis for multiple comparisons. Statistical analysis of depolarization-response curves involved calculating the non-linear fit of each curve and then comparing the 95% confidence interval for the curves. Non-overlapping 95% confidence intervals were taken as an indication of statistical significance.
Results
Identification
To analyze whether splice variants for the mCB1 receptor do exist, primers designed to amplify the sequence coding for the N-terminal extracellular domain of the mCB1 receptor were used in a PCR on cDNA templates from several brain tissues (forward primer binding to À4 to +20 and reverse primer binding to +203 to +284, counting the coding sequence start as +1, Fig. 1a ). Gel electrophoresis of the PCR products showed a band of approximately 300 bp corresponding to the unspliced mCB1 receptor sequence and two less abundant, smaller products for some of the template cDNAs (e.g., from hippocampus, basolateral amygdala; Fig. 1b) . The 300 bp band (corresponding to mCB1), and the gel areas between 150 and 250 bp and between 100 bp and 150 bp were excised and DNA was extracted. A second PCR on the extracted DNA resulted in strong, distinct bands of approximately 300 bp (corresponding to mCB1, 306 bp), 190 bp and 120 bp separated on an agarose gel. The PCR products were purified and subcloned, and insert DNA was sequenced. Alignment of the resulting sequence from the 190 bp PCR product with the sequence of the mCB1 receptor showed 100% sequence identity up to +103, then a gap corresponding to an intron of 117 bp and again 100% sequence identity from +220 (Fig. 1c) . The 120 bp PCR product had 100% sequence identity up to +87, then a gap corresponding to an intron of 186 bp and again 100% sequence identity from +274. As the intron sizes of 117 bp and 186 bp are divisible by three, and there is no alternative ATG upstream of the exon junction, it is highly likely that the same start codon for mCB1 is used for mCB1a and mCB1b. Comparison of the splice donor and acceptor sites with the conserved sequences (Lim and Burge 2001) showed that the donor site for mCB1a or mCB1b contains AG/GA or AG/TA at the 3' end/5' start of the intron, instead of the canonical AG/GT, respectively. Investigation of the splice acceptor sites of mCB1a and mCB1b revealed the presence of the canonical AG at the 3' splice site with an upstream region with enrichment of pyrimidine and the presence of the conserved G at the 5' site of the acceptor exon for both variants.
Quantification
To compare the expression levels of the novel splice variants mCB1a and mCB1b with those of mCB1, Taqman qPCR assays (primer-probe pairs) were used to selectively detect mCB1a or mCB1b. The reverse primers were designed to overlap the exon junctions in the coding sequences of mCB1a or mCB1b (Fig. 2a) . To detect the overall amount of all isoforms of the mCB1 receptor, an assay amplifying a sequence in the transmembrane domain was used. The expression levels of mCB1a and mCB1b were normalized to the expression level of all isoforms. Quantification revealed that both mCB1a and mCB1b have very low expression levels, between 0.02% and 0.1% relative to the overall mCB1 receptor level in all the analyzed brain tissues of C57Bl/6N mice ( Fig. 2b ; n = 5). The expression level of mCB1b was significantly lower than the expression of mCB1a in the infralimbic cortex (p < 0.001) and cerebellum (p < 0.001), with no significant difference in the hippocampus (p = 0.098).
Protein variants and potential differences in N-linked glycosylation
To analyze the molecular weight of mCB1a and mCB1b and compare it with the molecular weight of mCB1, western blots of whole-protein extracts from stably transfected cells were performed (Fig. 3a) . The calculated molecular weights are 53.9 kDa for HA-mCB1, 49.7 kDa for HA-mCB1a, and 47.0 kDa for HA-mCB1b. In the N-terminal extracellular tail, mCB1 has two putative N-linked glycosylation sites with the consensus sequence Asn(N)-X-Ser(S)/Thr(T) at amino acid positions 77 and 83 (Fig. 3b) . Glycosylated 
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Signaling efficiencies of mCB1 and the two novel splice variants mCB1a and mCB1b
The CB1 receptor is known to rapidly internalize following binding of several agonists and receptor activation (Hsieh et al. 1999) . To investigate whether the modified N-termini of mCB1a and mCB1b influence trafficking of the receptors upon activation, agonist-induced internalization was analyzed by confocal imaging (Fig. 4a) . After 1 h treatment with the synthetic CB1 receptor agonist WIN55,212-2 at a concentration of 1 lM, surface receptor loss was stronger for mCB1a ( Fig. 4a columns iii and iv) and mCB1b ( Fig. 4a columns v and vi) than for unspliced mCB1 (Fig. 4a columns  i and ii). Internalization was then quantified using on-cell western analysis. Cells expressing mCB1, mCB1a, or mCB1b were stimulated with different concentrations of WIN55,212-2 and after 1 h, the amount of receptors on the surface was quantified. Starting from a concentration of 5 nM or 10 nM, respectively, mCB1a and mCB1b showed greater internalization than the unspliced mCB1 receptor upon treatment with increasing agonist concentrations (Fig. 4b) . Analysis of the time course of surface receptor loss after stimulation with 1 lM WIN55,212-2 showed that shortly after stimulation (5 min) more mCB1a is internalized compared to mCB1b (Fig. 4c) . Fifteen minutes after stimulation with agonist, mCB1a shows greater internalization than unspliced mCB1. Between 30 min and 2 h after stimulation, both mCB1a and mCB1b showed similar internalization, which was significantly greater than that of the unspliced mCB1 receptor. Analysis of receptor trafficking to different concentrations of WIN55,212-2 was also measured in the presence of CB1 inverse agonist. 10 nM SR141716 caused a shift to the right in the WIN55,212-2 dose-response curve for all three mCB1 variants (Fig. 5a ). The strongest EC 50 shift for mCB1a suggests a potentially higher affinity for SR141716 of this splice variant (Fig. 5b) .
To analyze whether the splice variants differentially influence downstream signaling pathways, activation of the MAPK pathway was investigated since CB1 receptor activation leads to phosphorylation of p42/p44 MAPK (Bouaboula et al. 1995) . Stimulation of cells expressing the mCB1 receptor with 100 nM WIN55,212-2 resulted in a transient elevation of p44/42 MAPK phosphorylation with a peak activation of 150% over baseline at 5 min (Fig. 6) . Cells expressing mCB1a showed a similar response to cells expressing mCB1. Stimulation of cells expressing mCB1b led to significantly less MAPK phosphorylation at 5 min with a slightly delayed peak response of 50% over basal activation at 7.5 min. mCB1 and splice variant receptors signal similarly in autaptic hippocampal neurons Depolarization of autaptic hippocampal neurons can result in a form of retrograde inhibition termed DSE (Straiker and Mackie 2005) . This can be quantified by a series of successively longer depolarizations (50 ms, 100 ms, 300 ms, 500 ms, 1 s, 3 s, 10 s) resulting in progressively greater inhibition of neurotransmission (Straiker et al. 2011) . This produces a 'depolarization-response curve' that permits the characterization of some pharmacological properties of cannabinoid signaling including the calculation of an effective-dose 50 (ED 50 ), corresponding in this case to the duration of depolarization that results in 50% of the maximal response. We have previously reported that DSE is fully rescued by transfection of rCB1 into neurons cultured from CB1 receptor deficient mice (Straiker et al. 2011) . We found that transfection of mCB1 similarly rescued DSE [ Fig. 7a . No differences were found in the extent of DSE (maximal response) between the splice variants. A statistically significant difference in ED 50 's from mCB1 was seen for mCB1a but not mCB1b. However, the difference is modest and contrasts to our findings for hCB1 splice variants, where much larger differences in DSE were detected (Straiker et al. 2012 ).
Discussion
In this study, we identified two novel mouse CB1 receptor splice variants. The first variant, mCB1a, results from the excision of a 117 bp intron resulting in an in-frame deletion of 39 amino acids following amino acid residue 35. The second variant, mCB1b, results from the excision of a 186 bp intron resulting in an in-frame deletion of 62 amino acids, including two putative glycosylation sites, following amino acid residue 28.
As for the human CB1 receptor splice variants, both variants of the mouse CB1 receptor are generated by alternative splicing events in which a specific sequence may either be spliced out as an intron or be retained (Matlin et al. 2005) , which is the rarest mode of alternative splicing in mammals (Sammeth et al. 2008) . However, N-terminal splice variants were described to be unique for the human CB1 receptor (Howlett et al. 2002; Xiao et al. 2008) as the consensus splice donor and acceptor sequences present in the coding sequence of the human CNR1 gene are absent from the same positions in the mouse Cnr1 gene. The introns we found in the mouse CB1 receptor gene are at different positions from the human variants generated by alternative splicing. In addition, only the 3' end of the exons matches the splice consensus sequence (AG), whereas the 5' end of the introns differs from the consensus sequence (consensus: GT, mCB1a: GA, mCB1b: TA). The splice acceptor sites correspond to the consensus sequence (AG/G). The transcript variants of the mouse CB1 receptor that are generated by alternative splicing are expressed at very low levels compared with the unspliced CB1 receptor mRNA. This might be explained by less efficient assembly of the splice machinery at splice sites differing from the consensus sequences because of lower affinity interactions with the splicosome components.
The expression levels of the human CB1 receptor splice variants have only been estimated by semi-quantitative RT-PCR (Shire et al. 1995; Ryberg et al. 2005; Xiao et al. 2008; Bagher et al. 2013) and to our knowledge have not yet been analyzed by qPCR. The large N-terminus of the hCB1 receptor was shown to inhibit efficient receptor translocation across the membrane of the endoplasmatic reticulum (ER), leading to large amounts of misfolded CB1 receptor that are rerouted toward proteasome degradation (Andersson et al. 2003) . Shortening the N-terminus of the hCB1 receptor or the inclusion of a signal peptide for ER export greatly increases receptor stability, and both result in increased targeting to the cell surface (Andersson et al. 2003) . Partial truncation of the N-terminal tail of the human CB1 receptor was detected in various cell lineages in vitro, and is because of the fast proteolytic processing of de novo synthesized receptors in the cytoplasm prior to their translocation over the ER via a mechanism independent of the proteasome (Nordstr€ om and Andersson 2006). Co-expression of the hCB1 receptor and each of the splice variants increased cell surface expression of the hCB1 receptor in HEK cells (Bagher et al. 2013) , but the cellular distribution in vivo still remains to be determined. We could not investigate the relative amount of mCB1a and mCB1b and their cellular distribution in vivo as there are no isoform-specific antibodies available, but it is conceivable that shorter N-terminal tails might facilitate the surface targeting of the murine splice isoforms.
To characterize possible differences in protein expression and signaling efficiencies, HA-tagged mCB1, mCB1a, or mCB1b were stably expressed in HEK cells. In western blots with whole-protein extracts, mCB1 and the splice variant (i, iii, and v) or stimulated with 1 lM WIN55,212-2 (ii, iv, and vi) for 1 h. Following agonist treatment, mCB1 and the splice variants mCB1a and mCB1b were internalized. Surface receptor loss was stronger for mCB1a and mCB1b. Cells were counter-stained with WGA (green) and DAPI (blue) to visualize cell membranes and nuclei, respectively. (b) Dose-response curve: Following 1 h exposure to increasing concentrations of WIN55,212-2, mCB1 (black) and the novel splice variants mCB1a (red) and mCB1b (blue) internalized in a concentration-dependent manner, with the internalization of the variants mCB1a and mCB1b being stronger at any agonist concentration than of the unspliced mCB1 receptor. (c) Time course: Cells expressing mCB1, mCB1a, or mCB1b were stimulated with 1 lM WIN55,212-2 and the loss of surface receptors with time was quantified. After 5 min, surface mCB1a was reduced compared with mCB1 and mCB1b. At later time points, mCB1a and mCB1b were reduced on the cell surface compared with mCB1. Data are mean AE SEM; n = 12 from four independent experiments; ***p < 0.001, **p < 0.01, *p < 0.5 in post hoc test versus mCB1;^p < 0.05 in post hoc test of mCB1a versus mCB1b. mCB1a had a higher molecular weight than calculated from the amino acid sequences, but variant mCB1b was running as expected for its calculated molecular weight. An elevated molecular weight was previously described for the mature, glycosylated CB1 receptor in several species (Song and Howlett 1995; Onaivi et al. 1996; Andersson et al. 2003) . In the N-terminal extracellular tail, CB1 has two putative Nlinked glycosylation sites with the consensus sequence Asn (N)-X-Ser(S)/Thr(T) at amino acid positions 77 and 83 that are conserved in human, rat, and mouse. In the rat, both potential N-linked glycosylation sites are glycosylated, as treatment with endoglycosidase shifted the 64 kDa band to two 59 kDa and 53 kDa bands (Song and Howlett 1995) . In the splice variant mCB1a, these putative glycosylation sites are still present, whereas in mCB1b, they are removed by splicing, thus explaining the lower molecular weight. The functional significance of the N-glycosylation in the Nterminal domain of the CB1 receptor is not yet clear (Basavarajappa et al. 2008) . Human CB1 receptor with deletion of the first 89 amino acids (and thus, the two putative N-glycosylation sites), remained stably expressed at the cell surface, suggesting that N-linked glycosylation may not be required for transport of CB1 receptor to the plasma membrane (Andersson et al. 2003) . However, in that study, receptor trafficking upon stimulation was not analyzed. In other GPCRs (e.g., b-adrenergic receptors and muscarinic receptors), mutations of N-glycosylation sites abolished glycosylation, but had no obvious effect on receptor expression and function (Dohlman et al. 1991) . In recent studies, a crystal structure of the human CB1 receptor was determined (Hua et al. 2016; Shao et al. 2016) . A truncated CB1 receptor lacking the first 89 residues maintained basic inverse-agonist and agonist-binding properties, and the membrane-proximal N-terminal extracellular surface of CB1 formed a critical part of the ligand binding pocket. The ligand binding pocket is capped by the N-terminal loop interactions (Met103 N-term and Ile105 N-term ), which are still present in mCB1a and mCB1b.
The mCB1a and mCB1b splice variants demonstrated significant differences from mCB1 in agonist-induced internalization analyzed in stably expressing cell lines. Both novel splice variants had increased surface receptor loss in response to increasing concentrations of the agonist WIN55,212-2. Furthermore, the time course of internalization in response to 1 lM WIN55,212-2 was different, as mCB1a and mCB1b showed significantly faster internalization together with a stronger reduction in surface receptors compared with the unspliced mCB1 receptor. As the two splice variants with shortened N-termini showed very similar trafficking to each other, it is unlikely that the differences in phosphorylation was quantified in HEK293 cells stably expressing mCB1 (black), mCB1a (red) or mCB1b (blue) after stimulation with 100 nM WIN55,212-2. Cells expressing mCB1b showed a strongly reduced response compared with cells expressing mCB1 or mCB1a. Data are mean AE SEM; n = 9 from three independent experiments; ***p < 0.001 in post hoc test versus mCB1 or mCB1a.
N-linked glycosylation induced the increased surface receptor loss. Thus, either shortening of the N-terminal tail or the loss of a specific functional domain formed by amino acids missing in the splice variants leads to the observed stronger internalization. It was previously shown that phosphorylation of residues in the distal C-terminus play a role in endocytosis of the CB1 receptor (Daigle et al. 2008a) , but it has not yet been studied whether the N-terminal tail is involved in the regulation of receptor trafficking.
Agonist-induced stimulation of cells expressing the mCB1 receptor resulted in a transient activation of p44/42 MAPK phosphorylation with the classical response (Dalton and Howlett 2012 ): a maximal response in the first 5 min followed by a rapid decline after 5-10 min. Cells expressing mCB1a showed a similar response to cells expressing mCB1. Stimulation of cells expressing mCB1b led to significantly decreased p44/42 MAPK activation at 5 min with a lower and slightly delayed peak after 7.5 min. The rapid decline after agonist-induced p44/42 MAPK activation was similar for mCB1b as compared with mCB1 and mCB1a. Previously, it was shown that the duration of p44/42 MAPK activation by the CB1 receptor is regulated by receptor desensitization (uncoupling of receptor signal transduction) and not by internalization of the receptor (Daigle et al. 2008a) . The rapid decline in ERK phosphorylation after 5-10 min involves protein kinase A inhibition and serine/threonine phosphatase activation (Dalton and Howlett 2012) . As the rapid decline of p44/p42 MAPK phosphorylation was similar for mCB1, mCB1a, and mCB1b, receptor desensitization seems to be unchanged in the splice variants. However, the peak p44/42 MAPK activation is significantly lower in cells with stable expression of mCB1b. It has been shown that the maximal response of p44/p42 MAPK activation depends on receptor-stimulated, ligand-independent transactivation of [black, n = 7, included from (a) for reference], mCB1a (red, n = 4), and mCB1b (blue, n = 5) (d) Bar graph displaying EC 50 AE95% confidence interval (CI) show only modest, though statistically significant, difference in signaling between mCB1 and mCB1a. *Indicates non-overlapping 95% CIs. See Methods for experimental and statistical details.
multiple receptor tyrosine kinases, requires G i/o bc subunitstimulated phosphatidylinositol 3-kinase activation and Src kinase activation, and is modulated by inhibition of cAMP/ PKA (Dalton and Howlett 2012 ). Thus, it is possible that in cells expressing the mCB1b variant, one or several of these kinases are not efficiently recruited. One might speculate that differences in N-linked glycosylation of the N-termini could account for the different maximal responses, as it was also shown that the human splice variant hCB1a, which also lacks two putative glycosylation motifs, also displayed a reduced MAPK activity after agonist-induced stimulation (RinaldiCarmona et al. 1996) . However, in that study dosedependent MAPK activation was measured after 10 min. At this time point, MAPK activity would be expected to decline from the maximal response. The possibility that loss of N-linked glycosylation of the N-terminus leads to reduced peak MAPK activation needs to be carefully tested by comparing the maximal p44/p42 MAPK activation in CB1 receptors with mutations in one or several of the glycosylated Asn residues in the N-terminus. Furthermore, it would be interesting to analyze the maximal response in these mutants upon inhibition of the kinases that were shown to be involved in the strength of p44/p42 MAPK activation (Dalton and Howlett 2012) . In contrast to our results in MAPK and internalization assays, cannabinoid-receptor-mediated inhibition of neurotransmission in autaptic hippocampal neurons was similar between fulllength receptor and either splice variant. Although statistically significant for mCB1a versus mCB1, the differences were quite modest in comparison to our findings for hCB1 (Straiker et al. 2012) . One explanation for the difference between signaling pathways is that the splice variants exhibit pathway dependence in their signaling. They might therefore profoundly alter MAPK-mediated signaling while leaving neurotransmission unaltered. This finding also contrasts with our previous findings in neurons for human splice variants (Straiker et al. 2012) ; in that study we found that the splice variants substantially altered DSE. It should be noted that DSE represents one of several identified forms of neuromodulation mediated by cannabinoids (reviewed in Kano et al. 2009 ). Hence, the splice variants may differentially alter various forms of cannabinoid-mediated neuronal plasticity.
The physiological relevance of the novel splice variants of the mouse CB1 receptor is not yet clear, and might be expected to be modest because of their low expression on mRNA level. However, the splice variants can be valuable tools to improve our understanding of CB1 receptor signaling and trafficking, in particular the role of the N-terminal domain and conformational alterations brought upon by posttranslational modifications. and the US National Institutes of Health (DA011322 and DA021696 to KMackie). We thank Anne Bicker and Markus Hahn for their work on the project and Ruth Jelinek, Martin Purrio, and Andrea Conrad for excellent technical assistance. The authors declare no conflict of interest.
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